Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00456495 · ClinicalTrials.gov registry record · Phase 1
Effect of Ranibizumab on Malignant Conjunctival Neoplasia
A Phase 1 study of Conjunctival Neoplasms, sponsored by The New York Eye Cancer Center.
- Completed
- Registry status
- Phase 1
- Development phase
- 5
- Enrollment target
- 1
- Study location
NCT00456495 is a Phase 1 study of Conjunctival Neoplasms that has completed, run by The New York Eye Cancer Center. The registered enrollment target is 5 participants. The trial reports 1 study location across 1 state.
The verdict
NCT00456495, a Phase 1 study of Conjunctival Neoplasms, has completed, sponsored by The New York Eye Cancer Center.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 5 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this study is to test the safety and tolerability of subconjunctival injection of ranibizumab in the treatment of malignant conjunctival neoplasia using the incidence and severity of adverse events. Our secondary objective is to assess the efficacy of ranibizumab treatment on malignant conjunctival neoplasia by evaluating tumor destruction or reduction as documented by slit-lamp photography and ultrasonographic imaging and the regression of blood vessels.
Conditions Studied
Interventions
- DRUG ranibizumab
Study Locations (1)
New York
- The New York Eye Cancer Center - New York
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 5 participants |
| Start Date | 2007-03 |
| Est. Completion | 2010-09 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00456495
The ClinicalTrials.gov registry entry for NCT00456495 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 5 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is The New York Eye Cancer Center, which has 3 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Conjunctival Neoplasms appearing as the primary indexed condition, and to 1 intervention - of which ranibizumab is the first listed.
NCT00456495 reports 1 study location spanning 1 distinct geographic area - top geographies include New York.
Frequently Asked Questions
What is clinical trial NCT00456495 about?
NCT00456495 is a clinical study titled "Effect of Ranibizumab on Malignant Conjunctival Neoplasia". The purpose of this study is to test the safety and tolerability of subconjunctival injection of ranibizumab in the treatment of malignant conjunctival neoplasia using the incidence and severity of adverse events. Our secondary objective is to assess the efficacy of ranibizumab treatment on maligna...
What is the current status of trial NCT00456495?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 5 participants. The study started on 2007-03. Estimated completion is 2010-09.
What conditions does trial NCT00456495 study?
This clinical trial studies the following conditions: Conjunctival Neoplasms.
What interventions are being tested in trial NCT00456495?
The interventions under investigation include: ranibizumab (DRUG).
Who is sponsoring clinical trial NCT00456495?
This trial is sponsored by The New York Eye Cancer Center, which has 3 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00456495 being conducted?
This trial has 1 study location across New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.